Western University

Scholarship@Western
Brain and Mind Institute Researchers'
Publications

Brain and Mind Institute

8-1-2021

Treatment resistance: a time-based approach for early
identification in first episode psychosis
Kara Dempster
Dalhousie University, Faculty of Medicine

Annie Li
Schulich School of Medicine & Dentistry

Priyadharshini Sabesan
The University of Western Ontario

Ross Norman
The University of Western Ontario

Lena Palaniyappan
The University of Western Ontario, lpalaniy@uwo.ca

Follow this and additional works at: https://ir.lib.uwo.ca/brainpub

Citation of this paper:
Dempster, Kara; Li, Annie; Sabesan, Priyadharshini; Norman, Ross; and Palaniyappan, Lena, "Treatment
resistance: a time-based approach for early identification in first episode psychosis" (2021). Brain and
Mind Institute Researchers' Publications. 1022.
https://ir.lib.uwo.ca/brainpub/1022

Journal of

Personalized
Medicine
Article

Treatment Resistance: A Time-Based Approach for Early
Identification in First Episode Psychosis
Kara Dempster 1,† , Annie Li 2 , Priyadharshini Sabesan 3 , Ross Norman 3,4 and Lena Palaniyappan 3,4,5, *
1
2

3

4
5

*
†



Citation: Dempster, K.; Li, A.;
Sabesan, P.; Norman, R.;
Palaniyappan, L. Treatment
Resistance: A Time-Based Approach
for Early Identification in First
Episode Psychosis. J. Pers. Med. 2021,
11, 711. https://doi.org/

Department of Psychiatry, Dalhousie University, Halifax, NS B3H 2E2, Canada; Kara.Dempster@nshealth.ca
Department of Anaesthesia, Schulich School of Medicine & Dentistry, Western University,
London, ON N6A 5B7, Canada; Annie.Li@lhsc.on.ca
Department of Psychiatry, Western University, London, ON N6A 5B7, Canada;
Priyadharshini.Sabesan@lhsc.on.ca (P.S.); rnorman@uwo.ca (R.N.)
Lawson Health Research Institute, London, ON N6C 2R5, Canada
Robarts Research Institute, Western University, London, ON N6A 5B7, Canada
Correspondence: lpalaniy@uwo.ca
In partial fulfillment of Post Graduate thesis.

Abstract: Although approximately 1/3 of individuals with schizophrenia are Treatment Resistant
(TR), identifying these subjects prospectively remains challenging. The Treatment Response and
Resistance in Psychosis working group defines <20% improvement as an indicator of TR, though
its utility in First Episode Schizophrenia (FES) remains unknown. In a prospective cohort of FES
(n = 129) followed up for 5 years, we evaluated two improvement thresholds for ‘probable TR’;
<20% and <50% based on positive, negative, and total symptoms. We ascertained (1) the ecological
validity (i.e., the ability to identify an expected subgroup of 1/3rd of patients); (2) the predictive
validity (i.e., ability to predict poor global functioning) and (3) the clinical utility (association with
clozapine use at the 5th year). Using the criteria of a total symptom reduction of <50% or negative
symptom reduction of <20% resulted in ‘probable TR’ rates of 37% and 33%, respectively. Using
<20% positive or total symptoms criteria resulted in very low rates, indicating minimal utility in
FES. <50% total symptom criterion best predicted the global functioning over 5 years. Clozapine use
was only predicted by positive symptom criterion. Prospective characterization of TRS is possible at
6 months after FES through a time-based approach using a 50% threshold for symptom change in
treatment-adherent patients.
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1. Introduction
Approximately one third of patients with schizophrenia [1,2] continue to experience
symptoms despite treatment with dopamine-blocking antipsychotic agents. Treatment
resistance (TR) occurs early in the illness trajectory [3], though clinical identification is often
delayed [4]. TR has been primarily defined on the basis of measuring positive symptom
response to sequential antipsychotic trials, with most cases identified retrospectively in
patients with chronic schizophrenia [5]. A large body of evidence supports the existence
of a sizeable subgroup of patients who are unlikely to respond optimally to first-line
dopaminergic treatments, and are identifiable in first episode clinics through chart reviews
(Demjaha et al., 2017; Demjaha et al., 2014) [6,7]. Lally and colleagues traced the records of
246 patients with FES from a single site over 5 years and estimated 33% to meet the criteria
for TR; of these, only 50% were commenced on clozapine [8].
While the sequential failure of 2 adequately dosed antipsychotics is used to define TR,
in practice, more than 4 antipsychotics are tried often in higher doses and in combinations,
as practitioners fail to suspect TR earlier in the illness course [7]. To facilitate early identification of TRS, the Treatment Response and Resistance in Psychosis (TRRIP; [5]) working
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group published consensus guidelines defining treatment resistance. According to these
guidelines, insufficient response is defined as <20% improvement on positive or negative
symptom domains after 6 weeks of adhering to therapeutic dose for each of 2 different
antipsychotics. However, implementing these recommendations for early identification
of TR in FES is challenging for various reasons; (1) In FES samples, the response rates for
positive symptoms are generally high [9,10]; it is unclear whether the threshold of <20%
symptom improvement will be appropriate to identify the TRS subgroup (2) the value
of measuring negative symptoms when defining TR in FES has not yet been characterized, as positive symptoms continue to assume a central role when evaluating treatment
response [11], especially in early stages of psychosis (3) The recommended use of lowest
possible effective doses and higher rates of apprehension for side effects when treating
FES [12] prolongs treatment duration with a single agent further than 6 weeks in most cases
(4) Oral medications are the most common route of administration in FES clinics [13]; but
adherence is rarely measured on a routine basis. As a result, a determination of TR in FES
takes much longer than the consensus recommendations, with a 4 to 9.7 years lag between
a diagnosis of FES and the start of clozapine [14,15]. Substantial disability accumulates
during this time, with the delay eventually reducing the probability of responding to
clozapine as well [16–18].
Given the practical challenges in adopting conventional ‘trial-based’ TRS criteria in
FES clinics, we study the utility of applying a “time-based” response cut-off, irrespective
of the number of antipsychotic trials in one of the few FES samples in the world that was
prospectively followed up for 5 years. We had two specific aims:
(1)

(2)

To identify the symptom domains and thresholds that define a “probable TR” subgroup in a prospective manner in FES samples as early as 6 months after presentation.
We studied the utility of a 20% response threshold (as defined by TRIPP; [5]) as well as
a more stringent 50% response threshold (identified as a “good response” cut-off for
clinical trials by Aboraya et al., (2017) [19] in the domains of positive, negative, and
total symptoms 6 months following FES. In keeping with previous literature [1,2], and
the single-site data from a 5-year follow-up of FES, we hypothesized that the most
valid criteria would categorize approximately 33% of the sample as probable TR.
To test the predictive and clinical validity of the various “probable TR” definitions at
6 months by assessing whether global functioning over 5 years and clozapine use at
the 5th year could be reliably predicted on the basis of these definitions. Given the
high response rates for positive symptoms expected in FES, we hypothesized that
the use of 50% threshold as well as the inclusion of negative symptoms would be
important in characterizing probable TR in a FES sample. Nevertheless, given the
historical focus on positive symptoms when prescribing clozapine [11], we expected
probable-TR defined as per positive rather than negative symptom thresholds to
relate to eventual clozapine use.

2. Materials and Methods
2.1. Sample Recruitment
Data were analysed retrospectively using a longitudinal, naturalistic sample of 129 patients treated at the Prevention and Early Intervention Program for Psychosis (PEPP) in
London, Ontario between February 1997 and February 2002. This program provides assessment and treatment to individuals presenting with first-episode, non-affective psychoses
using an assertive case-management model. Criteria for acceptance to the program include
age between 16 and 50, symptoms meeting criteria for a Diagnostic and Statistical Manual
of Mental Disorders (Fourth Edition) (DSM-IV; APA, 2000) psychotic disorder, and having
never received prior antipsychotic treatment for greater than one month. All patients were
treated within the same program. Approval for the study was obtained from the University
Human Ethics Committee for Health Sciences at the University of Western Ontario. Written
informed consent was obtained from all subjects involved in the study.
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2.2. Clinical Assessment
Diagnoses were established using the Structured Clinical Interview for DSM-IV (First
& Gibbon, 1997) by trained research assistants, and confirmed by two senior psychiatrists
and a clinical research psychologist, with consensus diagnosis conferences occurring at
one-year follow-up. Individuals that ended up meeting criteria for a mood disorder
with psychotic features, or any substance induced psychosis, were excluded from the
analysis. Positive and negative symptoms of psychosis were assessed using the SANS
(Andreasen, 1983) and SAPS (Andreasen, 1984) at baseline, and at months 1, 2, 3, and 6.
Interrater reliability on the SAPS and SANS demonstrated agreement within one point
93% of the time [20]. Total symptoms were defined as the total score of the SAPS and
SANS. Duration of untreated illness (DUI) was calculated as the period between the
onset of any psychiatric symptoms and the time to antipsychotic treatment. Duration
of untreated psychosis (DUP) was defined as the time between the onset of psychotic
symptoms and the time to adequate antipsychotic treatment. Premorbid adjustment
was measured using the Premorbid Adjustment Scale (PAS; [21]), with higher values
indicating worse premorbid functioning. Symptom change overtime was calculated as the
difference between a particular symptom domain from baseline divided by the baseline
symptom score (eg positive symptom improvement over month 1 = (SAPS baseline-SAPS
month 1)/SAPS baseline)).
2.3. Assessment of Adherence
Adherence monitoring to medication treatment was accomplished via a weekly adherence log [22]. Adherence was scored on a scale of 0–4 (0 = not adherent, 1 = 0–25%,
2 = 25–50%, 3 = 50–75%, 4 = 75–100% of prescribed doses taken). Scores were obtained
through reports of case managers (who have frequent contact with patients and their
families), in discussion with the primary psychiatrist. Patient and family reports were
considered in making adherence assessments, as well as reviews of prescriptions and
pill counts. Individuals were considered to be adherent if they scored a 4, meaning their
compliance was estimated to be between 75–100%. Individuals that were not medication
adherent (scores of 0, 1, 2, or 3) based on 6-month adherence measures were not included
in the sample (n = 36 excluded from 129).
2.4. Probable Treatment Resistance Criteria
Probable TR status was investigated at 6 months after entry into the first episode
psychosis program based on meeting defined thresholds for symptom change from baseline,
in those who were medication adherent. For positive, negative, and total symptom domains,
we used 20%, and less than 50% improvement as cut-offs to identify subjects satisfying
“probable TR” criteria. Following identifying “probable TR” individuals, individual item
scores on the SAPS and SANS (as applicable) were examined at baseline to ensure that
individuals meeting criteria met the threshold of at least moderate severity (more than one
individual item >2) in terms of symptomology, as suggested by TRIPP ([5]).
2.5. Statistical Analysis
All statistical analyses were carried out using SPSS 25 (IBM Corp. Released 2017).
Goodness-of-fit tests based on chi-square statistics were performed on the 6 definitions
of probable TRS. We tested the observed proportions against the expected proportion
of 33% subjects being treatment resistant [1,2], as identified in FES cohorts over 5 years
by Lally and colleagues [6]. The definitions that identified the expected proportion of
patients were entered as independent predictor variables in 2 separate multiple regression
models, with the average of the GAF scores assessed annually over the next 5 years
and clozapine use by 5th year being the dependent variables. The definition with the
best predictive validity was used to identify ‘probable TR’. Chi-square analyses/t-tests
were then performed to determine the univariate relationship between baseline variables
(independent predictors) and probable TR identified by the extant criteria (dependent
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variables). For all t-tests, Levine’s test for homogeneity of variances was conducted. For
variables showing significant heterogeneity of variance, the corrected p-value was used,
after adjusting the degree of freedom using a Satterthwaite approximation as implemented
in SPSS (v25.0). Logistic regression analyses were then applied to create a model to predict
membership within the probable TR group (dependent variable) based on the factors found
to be significantly associated in the univariate analysis (independent predictors). MannWhitney U tests were used to compare the number of antipsychotic medication trials in
individuals with probable and non-probable TR for each symptom improvement threshold.
A statistical significance defined by a threshold of p < 0.05 was used for all analyses.
3. Results
3.1. Final Sample
129 patients met criteria for a first episode schizophrenia spectrum disorder and were
considered for inclusion in the analysis. Using only individuals that were medication
adherent, resulted in a sample size of 93 FES patients (74 male and 19 female), while 36
(30.23%) were not included due to being categorized as non-adherent. One male was
missing SANS scores and therefore the total sample size was 92 for analyses assessing
negative symptoms. The mean age at onset of psychosis was 24.19. Per diagnostic consensus conference, 70 met criteria for schizophrenia, 20 for schizoaffective disorder, and
2 for schizophreniform disorder. 56 were inpatients at study entry, while 37 were outpatients. The mean chlorpromazine equivalence at 6 months was 227.35 mg. (See Table 1 for
further details).
Table 1. Clinical and demographic characteristics of the final sample.
Characteristic

Sample (n = 92)

Age
Gender (M/F)
Age of onset in years (SD)
DUP (mean in weeks) (SD)
DUI (mean in weeks) (SD)
SAPS baseline (M/SD)
SANS baseline (M/SD)
Substance abuse/dependence (Y/N)
Mode of onset (I/A)
Family History (Y/N)

25.72 (7.97)
73/19
24.27 (8.1)
74.53 (112.5)
292.3 (275.1)
10.5 (3.58)
12.7 (5.17)
23/69
67/23
32/49

DUP = duration of untreated psychosis. DUI = duration untreated illness. TR = Treatment Resistance.
SANS/SAPS = Scale for the Assessment of Negative/Positive Symptoms. Mode of onset (data from 90 subjects)—
I = insidious. A = acute. Y = yes. N = no. M = male. F = female. SD = standard deviation.

3.2. Goodness of Fit for Various Definitions for Probable TR
We first investigated the prevalence of probable TR at 6 months using 20% and 50%
symptom improvement thresholds for positive, negative and total symptoms (see Table 2).
Total symptom probable TR < 50% and negative TR < 20% at 6 months resulted in rates
closest to those previously described in the literature [1,2] (rates of 37% and 33% respectively). See Table 2 and Figure 1. We further tested the goodness of fit of these models
using one-sample chi-square tests with the null hypothesis being that the proportion of
TR individuals would be 33% for each criterion. The null hypothesis was rejected for all
definitions, with the exception of TR negative <20% (χ2 =0.01, p = 0.936, df = 1) and TR
total < 50% (χ2 = 0.65, p = 0.420, df = 1), meaning the expected frequency of TR for these
criteria was approximately 33%. Of those meeting criteria for TR negative < 20%, 77% also
met criteria for total symptom TR < 50%, suggesting there was a high degree of overlap
between these two categorizations of TR. See Appendix A and Supplementary Tables S1
and S2 for predictors of probable TR based on total <50% criterion.
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Table 2. Rates of Probable TR and mean number of antipsychotic trials using various criteria.
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Domain

Criteria

Probable TR (%)

AP Trials
(M/SD)

Non TR (%)

AP Trials

Positive

<20%

2 (2.2)

2.00/1.41

91 (97.8)

1.30/0.50

closest
to those previously
described
[1,2] (rates
37% and 1.30/0.05
33% respecsymptoms
<50%
13 (14)in the literature
1.38/0.65
80 of
(86)
tively). See Table 2 and Figure 1. We further tested the goodness of fit of these models
Negative
<20%
30 (33)
1.23/0.50
62 (67)
1.34/0.54
using
one-sample<50%
chi-square tests
with the null
hypothesis being
that the proportion
symptoms
56 (60.8)
1.30/0.54
36 (39.13)
1.31/0.52 of
TR individuals would be 33% for each criterion. The null hypothesis was rejected for all
Total
<20%
11 (12)
1.36/0.67
81 (88)
1.29/0.51
definitions, with the exception of TR negative <20% (χ2 =0.01, p = 0.936, df = 1) and TR
symptoms
<50%
34 (36.96)
1.32/0.59
58 (63.04)
1.29/0.49
total < 50% (χ2 = 0.65, p = 0.420, df = 1), meaning the expected frequency of TR for these
AP trials = number of antipsychotic trials; M = mean; SD = standard deviation; TR = treatment resistance. The non
criteria was approximately 33%. Of those meeting criteria for TR negative < 20%, 77% also
TR% are the same as response rates at 6 months time for each domain. For example, 63.04% of treatment-adherent
met criteria
total
symptom
TR in< total
50%,symptoms,
suggesting
was aahigh
of overlap
patients
showedfor
a 50%
or greater
reduction
whilethere
86% showed
50% ordegree
greater reduction
in
between
these
two
categorizations
of
TR.
See
Appendix
A1
and
Supplementary
Tables S1
positive symptoms domain.
and S2 for predictors of probable TR based on total <50% criterion.
Probable non-TR%
39%

Negative 50

61%
63%

Total 50

37%
67%

Negative 20

33%
86%

Positive 50

14%
88%

Total 20
Positive 20

Probable TR%

12%
98%
2%

Figure1.1.Distribution
Distribution
of probable
treatment
resistance
6-months
after antipsychotic
initiation.
Figure
of probable
treatment
resistance
6-months
after antipsychotic
initiation.
Across
Across the 3 domains of symptom measures (positive, negative and total), the use of either 20% or
the 3 domains of symptom measures (positive, negative and total), the use of either 20% or 50% cut-off
50% cut-off (y axis) for defining treatment response by 6 months after induction to a first-episode
(y axis) for defining treatment response by 6 months after induction to a first-episode program results
program results in different proportions of patients being identified as probable cases of treatment
in
different (x-axis).
proportions of patients being identified as probable cases of treatment resistance (x-axis).
resistance

3.3. Ability to Predict Poor Global Functioning over the Next 5 Years

Table 2. Rates of Probable TR and mean number of antipsychotic trials using various criteria.

With total symptom improvement <50% and negative symptom improvement <20% at
Criteria
TR predictors,
(%) AP trials(M/SD)
Non
TR (%)
AP Trials
6 months as Probable
independent
multiple regression
analysis
was conducted
to predict
the average of 5 annual
of GAF scores (n =9192(97.8)
for 3 observations;
n = 82 for
<20%
2 (2.2) observations
2.00/1.41
1.30/0.50
Positive symptoms
year 4; n = 72 for year
5; mean imputed
for missing values).
<50%
13 (14)
1.38/0.65
80We
(86)tested for multicollinearity
1.30/0.05
using
the
variance
inflation
factor
(VIF)
between
the
2
predictors
using
a
threshold
Negative symp<20%
30 (33)
1.23/0.50
62 (67)
1.34/0.54 of 2,
(with
a
tolerance
of
less
than
0.9
for
all
predictors)
and
no
evidence
of
multicollinearity
toms
<50%
56 (60.8)
1.30/0.54
36 (39.13)
1.31/0.52
detected.
The
model
was
significant
(F
=
5.52
p
=
0.006),
with
the
probable
TR
(defined by
<20%
11 (12)
1.36/0.67
81 (88)
1.29/0.51
Total symptoms
total symptoms <50% improvement) being the significant predictor (t = −3.15, p = 0.002),
<50%
34 (36.96)
1.32/0.59
58 (63.04)
1.29/0.49
while 20% negative symptom criteria was not a significant predictor (t = 0.94, p = 0.35) of
AP trials = number of antipsychotic trials; M = mean; SD = standard deviation; TR = treatment resistance. The non TR%
the dependent variable GAF at 5 years.

Domain

are the same as response rates at 6 months time for each domain. For example, 63.04% of treatment-adherent patients
showed a 50% or greater reduction in total symptoms, while 86% showed a 50% or greater reduction in positive symptoms
3.4. Ability to Predict Clozapine Use by 5 Years
domain.

By year 5, 15 out of 92 patients (16.2%) with FES were on clozapine, lower than
the
expected
with
TRS.
Only
3 out of 15
were
it at year 2, indicating that
3.3. Ability to 33%
Predict
Poor
Global
Functioning
over
the receiving
Next 5 Years
most clozapine initiation occurred between 2 to 5 years of illness. With total symptom
With total symptom improvement <50% and negative symptom improvement <20%
at 6 months as independent predictors, multiple regression analysis was conducted to
predict the average of 5 annual observations of GAF scores (n = 92 for 3 observations; n =
82 for year 4; n = 72 for year 5; mean imputed for missing values). We tested for multicol-
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improvement <50% and negative symptom improvement <20% at 6 months as independent predictors, multiple regression analysis was conducted to predict the prescription of
clozapine at year 5 (dependent variable). The model was not significant (F = 1.45 p = 0.24),
with both total symptom <50% improvement (t = 1.71, p = 0.09) and <20% negative symptom improvement not being significant predictors (t = −0.92, p = 0.36). Following this
observation, we undertook a hierarchical regression analysis, wherein <50% total and
<20% negative symptom criteria were retained as Block 1 predictors, while <50% positive
symptom criterion was entered as Block 2. The R2 of the model increased from 0.03 to 0.11,
with the R2 change being significant (F = 7.78, p = 0.006), with <50% positive symptom
improvement at 6 months being a significant predictor of clozapine use at year 5 (t = −2.79,
p = 0.006). The diagnostic odds ratio for the various symptom improvement thresholds
at 6 months for future clozapine use is presented in Supplementary Material (Table S3),
indicating that the odds of clozapine use at 5th year was highest in those showing <50%
positive symptom improvement by 6 months. See Table 3 for a summary of results.
Table 3. Summary of results.

Domain

Positive Symptoms

Negative Symptoms

Total symptoms

Threshold

Ability to Select a 33%
Subgroup by
6 Months of FES

Ability to Predict Low
GAF over 5 Years

Ability to Predict
Clozapine Use by
5 Years

<20%

NO

-

-

<50%

NO

-

YES *

<20%

YES

-

-

<50%

NO

-

-

<20%

NO

-

-

<50%

YES

YES

NO

R2

FES = First Episode Schizophrenia; GAF = Global Assessment of Functioning * Based on a
change of a hierarchical regression analysis
with <50% total and <20% negative symptom criteria as Block 1 predictors, and <50% positive symptom criterion as Block 2.

3.5. Patterns of Antipsychotic Use
Overall, there were no significant differences in the number of antipsychotic trials
for either the <50% or <20% thresholds for either probable or probable non-TR, indicating
that the clinician prescribers were not able to foresee the later emergence of TR in this
sample. There were no significant differences in the number of antipsychotic medication
trials for those with probable and probable non-TR based on total symptom improvement
for the thresholds of <20% (U = 853.00, Z = −0.077, p = 0.939), or <50% improvement
(U = 840.0, Z = −0.187, p = 0.852). Similar results of no difference were also observed
for positive symptom criteria for the 20% improvement threshold (U = 871.5, Z = −0.657,
p = 0.511) or the 50% improvement threshold (U= 834.0, Z = −0.803, p = 0.422), and negative
symptom criteria for 20% improvement threshold (U = 744.0, Z = −1.22, p = 0.223) or the
50% threshold (U = 850.0, Z = −0.082, p = 0.935). Overall, these results indicate that there
were no systematic differences in sequential antipsychotic switching in the first 6 months of
entry to the first-episode program among patients with different response trajectories. See
Supplementary Table S4 for the range of doses used and different medications prescribed
in the 6 months period.
4. Discussion
This is the first study to our knowledge to investigate the applicability of response
thresholds proposed by TRIPP [5] in a FES sample. In addition, there have been no other
studies looking specifically at the importance of considering negative symptom persistence
in prospective characterisation of TR in early psychosis. We observe that (1) around 1/3rd
of FES subjects show <50% improvement in total symptoms at month 6; (2) this group
shows poor global functioning despite treatment over the next 5 years and (3) does not
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receive more antipsychotic trials than those who show >50% improvement at month 6.
We also observe that while <50% improvement in total symptoms at 6 months do not
predict later clozapine use, the same threshold when applied for positive symptoms,
identifies TR subjects treated with clozapine. These results indicate that identifying a
probable TR group in FES at 6 months irrespective of antipsychotic usage data is a viable
strategy for prospective and early identification of TRS. These observations inform the
timing (6 months), type of measurement (total symptoms) and decision thresholds (<50%
improvement) for suspecting TR, when adopting a Measurement Based Care approach in
FES clinics.
Our results suggest that at 6 months of treatment, the most ecologically valid definition,
based on the expected rate of 33% subjects having a resistant form of schizophrenia, is the
failure to improve in total symptoms by 50%, or negative symptoms by 20%. In keeping
with our hypothesis, inclusion of negative symptoms in defining TR appears to be crucial
to identify the probability of TRS in an acceptable proportion of individuals with FES.
Definitions of TR relying solely on positive symptomology were inadequate in identifying
cases of probable TR (probable TR rates were 2.2% for the 20% threshold, and 14% for
the 50% threshold) likely in keeping with the fact that positive symptom improvement is
robust early in the course of schizophrenia [23]. The 20% symptom improvement criteria
as suggested by TRIPP [5], seems effective when considering only negative symptom
improvement, but fails to identify the expected proportion of patients when positive
symptoms are considered in a FES sample. Our results provide preliminary evidence
that individuals with probable TR can be identified at as early as 6-months following FES,
regardless of the number of antipsychotic trials, and that inclusion of negative symptom
improvement is essential in risk-stratification for probable TR in early psychosis.
We have demonstrated the feasibility of prospectively identifying a group of FES
subjects that share the risk factors for later TR, even before 2 antipsychotic failures can be
observed. Active monitoring for probable TR in early intervention programs can aid in
treating these individuals at the earliest possible opportunity, and avoid interventional
relapse [24] and subsequent resistance [10]. Clozapine is the only antipsychotic medication
with superior efficacy in TR individuals [25] and current guidelines necessitate failure
of two antipsychotic agents prior to a trial of clozapine is initiated. The requirement of
consecutive antipsychotic trials may contribute to delays in clozapine initiation. Response
rates to clozapine following failed antipsychotic trials have been shown to be more robust in
patients with FES (75%) [3], relative to chronic samples (40%) [26] and therefore, developing
objective clinical indicators for earlier determination of clozapine eligibility is of pivotal
importance. As positive symptom improvement is significant at this early stage, focusing
exclusively on positive symptom improvement may lead to under-identification of TR
individuals, as shown in our work. It is worth noting that despite the uncertainty that
surrounds clozapine’s effectiveness for negative symptoms [25], the burden of negative
symptoms in early stages of schizophrenia predict later TR (Demjaha et al., 2017) [7].
Limitations: One of the most important limitations is the limited size of our sample;
of 129 prospectively followed-up subjects with FES, only 93 had sufficient treatment adherence, with 92 having the requisite clinical follow-up data in the first 6 months (29%
attrition). While this reduces the precision of our estimates of probable TR, such attrition is
not unexpected in naturalistic clinical settings. While formal assessments of medication
adherence were completed, antipsychotic serum levels were not performed. However, our
measure of assessing adherence has been validated, and has been shown to be related to pill
counts [27]. Symptom data were available at discrete intervals however, the relapse status
of individuals between assessments was not recorded for the purposes of this analysis.
It is possible that individuals who experienced relapse, particularly prior to 6 months
when TR status was assessed, may have been mislabelled as having inadequate response
simply because their symptoms were higher at the time of assessment secondary to relapse.
However, the fact that TR status at 6 months was associated with impaired symptom
improvement during the early months, suggests that for the majority, the development of
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TR was occurring early on, and was not simply related to an acute symptomatic relapse.
Certain service-utilization variables that were not considered in our regression analyses
may also affect the probable treatment resistance status, e.g., hospital admission status at
baseline. Nevertheless, when we compared the symptom burden at 6 months, we found no
significant difference in positive (t = 1.2. p = 0.21), negative (t = 0.72, p = 0.4) or total (t = 1.1,
p = 0.27) symptom burden between the patients who were initially hospitalized vs. those
who were not. This lack of difference may be due to the relatively shorter duration of hospital admission (PEPP is a community early intervention team that explicitly promotes early
discharge) and the lack of hospitalization data during the later course of illness. Finally, our
sample only included individuals assessed as being adherent with medication at 6 months,
and therefore, our findings relate specifically to the phenomenon of TR in the treatment
compliant individuals, and not necessarily TR in the overall schizophrenia population.
5. Conclusions
In a naturalistic practice setting, when considering treatment-compliant subjects, the
number of AP trials does not differ between probable TR and non-TR. In other words, in
the absence of the explicit clinical knowledge of the risk factors, pharmacological practice
does not change for patients who are likely to later need clozapine. This is an important
aspect to consider in our efforts aimed at mitigating the delay in timely clozapine use. Our
results suggest that irrespective of the number of AP trials attempted, if a patient with FES
shows less than 50% total symptom burden by 6 months of early intervention, then fasttracking to clozapine may be warranted. This highlights the need for measurement-based
decision-making in FES settings [28].
Supplementary Materials: The following are available online at https://www.mdpi.com/article/
10.3390/jpm11080711/s1, Table S1: Factors Associated with Probable TR (<50% improvement on
total symptoms).; Table S2: Binary logistic regression analysis of Probable TR total symptom <50%
improvement criteria. Table S3: Diagnostic Test Performance of Probable TR using various criteria.
Table S4: Details of medications prescribed at baseline and by 6 months.
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Appendix A
Factors associated with probable TR (total symptoms <50%) at 6 months: A logistic
regression analysis was conducted to predict TR total <50% criteria using all predictors
found to be associated with TR in univariate analyses. Patients meeting criteria for probable
TR based on having a less than 50% total symptom improvement had worse premorbid
functioning (M = 0.37, SD = 0.13) than patients not meeting probable TR on the basis of
this criteria (M = 0.28, SD = 0.17) (t(80) = −2.526, p = 0.014), a longer duration of untreated
illness (probable TR: M = 386.21, SD = 340.78; non TR: M = 236.31, SD = 211.28), (t(48.37)
= −2.31, p = 0.025), a lower baseline SAPS score (probable TR: M = 9.35, SD = 3.52; non
TR: M = 11.21, SD = 3.47), (t(90) = 2.463, p = 0.016) and less total symptom percentage
improvement over 1 month (probable TR: M = 16.39%, SD = 26.37; non TR: M = 37.38%,
SD = 23.46), (t(57) = 3.048, p = 0.003), and 2 months (probable TR: M = 20.87%, SD = 27.05;
non TR: M = 48.70%, SD = 29.83), (t(60) = 3.59, p = 0.001) (see Supplementary Table S1).
We tested for multicollinearity using the variance inflation factor (VIF) among the
predictors using a threshold of 2, (with a tolerance of less than 0.9 for all predictors)
with no evidence of multicollinearity detected. A test of the full model was significant,
indicating the model as a whole could reliably identify probable TR (total < 50%) (χ2 = 15.90,
p = 0.007, df = 5). Prediction success overall was 82.2% (96.9% for no probable TR and
46.2% for probable TR), indicating the model was much stronger at ruling out TR. In
analyzing the independent predictors in the model (see Supplementary Table S2), none
of the variables independently predicted TR status, although total symptom change over
2 months demonstrated trend-level significance (p = 0.059).
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